Navigation Links
Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting

ooking statements, which express the current beliefs and expectations of the management of GPC Biotech AG and Pharmion Corporation, including statements relating to results of the SPARC trial and statements relating to the potential efficacy and safety profile of satraplatin. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. In particular, there can be no guarantee that additional information relating to the safety, efficacy or tolerability of satraplatin may be discovered upon further analysis of data from the SPARC trial or analysis of additional data from other ongoing clinical trials for satraplatin. Furthermore, we cannot guarantee that satraplatin will be approved for marketing in a timely manner, if at all, by regulatory authorities nor that, if marketed, satraplatin will be a successful commercial product. We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2005, Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2007, its Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of either Pharmion or GPC Biotech. Forward-looking statements speak only as of the date on which they are made and neither Pharmion nor GPC Biotech undertakes any obligation to update these forward-looking statements, even if new information becomes availabl
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely ... a generation ago are returning. Measles was declared eliminated ... in 2014 as of August 15—the highest incidence in ... public health department declared whooping cough a problem of ... are getting sick and dying from these preventable diseases—in ...
(Date:8/29/2014)... Aug. 29, 2014  Abaxis, Inc. (NasdaqGS: ... instrumentation and consumables to the medical, research and veterinary ... and Chief Executive Officer, will present at the CL ... on Tuesday, September 9, 2014 at 12:30 p.m. ET. ... Place Hotel in New York City ...
(Date:8/29/2014)... 29, 2014 , Industry ... the inaugural Tweetchat taking place in real-time at ... organised by UBM Live , announces the ... a first of its kind global industry-wide Tweetchat ... supply chain, aimed to stimulate conversations on key ...
Breaking Medicine Technology:Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 3
... CARLSBAD, Calif., Nov. 22, 2011 Isis Pharmaceuticals, Inc. (NASDAQ: ... up to $14 million from Pfizer Inc. (NYSE: ... from Pfizer,s acquisition of Excaliard.  Upon closing of the acquisition, ... up to an additional $9.6 million could be paid to ...
... NEW YORK, Nov. 22, 2011 ... research report is available in its ... - Global Pipeline Analysis, Competitive Landscape ... http://www.reportlinker.com/p0685952/X-Ray-Systems---Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging ...
Cached Medicine Technology:Isis to Receive Up to $14 Million from Pfizer for Its Acquisition of Excaliard Pharmaceuticals 2Isis to Receive Up to $14 Million from Pfizer for Its Acquisition of Excaliard Pharmaceuticals 3Isis to Receive Up to $14 Million from Pfizer for Its Acquisition of Excaliard Pharmaceuticals 4X-Ray Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2X-Ray Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3X-Ray Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 4X-Ray Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 5X-Ray Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 6X-Ray Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 7X-Ray Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 8X-Ray Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 9X-Ray Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 10X-Ray Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 11X-Ray Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 12X-Ray Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 13
(Date:8/30/2014)... Daily Gossip reveals in its review a ... You program, who shows a unique formula to get inside ... method says that the program goes beyond mere attraction and ... You review indicates that the program was created by dating ... great techniques to make a man feel emotionally addicted. , ...
(Date:8/30/2014)... York (PRWEB) August 30, 2014 ... of Nutrition and Pharameuticals. Nutraceuticals is a source ... healthy ingredients from natural food sources. Nutraceutical ingredients ... benefits to the human body. Nutraceutical health products ... supplements, fortified foods and more. Although nature is ...
(Date:8/30/2014)... 2014 After offering hyperbaric oxygen ... the past several years, Dr. Roy Schmidt and ... announced a scholarship program for veterans who have ... meeting held this summer to discuss veterans’ needs ... have shed light on the large number of ...
(Date:8/30/2014)... August 30, 2014 Hundreds of Byetta ... continue to move forward in U.S. courts, Bernstein Liebhard ... PLC on July 31, 2014, Byetta and Bydureon (an ... product liability claims that allege the drugs caused pancreatitis, ... many of these claims are pending in a multidistrict ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
Breaking Medicine News(10 mins):Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... Star Scientific, Inc. (Nasdaq: STSI ) filed ... Securities and Exchange Commission. The company reported 2008 net ... net sales for 2007. However, volume sales of the ... increased 7.8% in 2008 compared to 2007. The wholesale ...
... From ,Democracy to Despotism, Cardinal Francis George WarnsAlert ... ProtectionsWASHINGTON, March 16 Cardinal Francis George is ... the Obama Administration to retain Health and Human ... workers.This is vital to keep the government from ...
... among Top 10 Companies for Supplier Diversity and for African ... Service Corporation (HCSC) as one of its Top 50 Companies ... In 2009, the company ranks 22, up 12 spots from ... 10 Companies for Supplier Diversity as well as the Top ...
... March 16 Coursework begins today as the American ... states to deliver needed dental care to underserved people ... developed by the ADA over the past several years, ... Dental Health Coordinator (CDHC). CDHCs are drawn from the ...
... Access to Medigap as Additional Coverage Option For ... 16 The National Kidney Foundation of Florida ... Representative Ritch Workman today for co-sponsoring proposed legislation ... for Florida,s end stage renal disease (ESRD) patients ...
... suggests close monitoring offers some men better quality of ... immediate treatment can be safe for men with low-risk ... finds. , The multi-center study of American and Canadian ... or if to treat men with low-risk prostate cancer ...
Cached Medicine News:Health News:Star Scientific Files Annual Financial Report 2Health News:Star Scientific Files Annual Financial Report 3Health News:Star Scientific Files Annual Financial Report 4Health News:Cardinal George Urges Catholics to Tell Administration: Keep Conscience Protections for Health Care Workers 2Health News:Cardinal George Urges Catholics to Tell Administration: Keep Conscience Protections for Health Care Workers 3Health News:Health Care Service Corporation Ranked as One of the Most Diverse Companies in the Country for 5th Consecutive Year 2Health News:Health Care Service Corporation Ranked as One of the Most Diverse Companies in the Country for 5th Consecutive Year 3Health News:Health Care Service Corporation Ranked as One of the Most Diverse Companies in the Country for 5th Consecutive Year 4Health News:ADA Launches Community Dental Health Coordinator Program to Provide Dental Care in Underserved Areas 2Health News:ADA Launches Community Dental Health Coordinator Program to Provide Dental Care in Underserved Areas 3Health News:The National Kidney Foundation of Florida Commends Senator Thad Altman, Representative Ritch Workman for Co-Sponsoring 'Common Sense' Legislation Widely Hailed as 'Good for Patients, Good for Taxpayers, Good for Florida' 2Health News:'Watchful Waiting' Safe With Low-Risk Prostate Cancers 2
Anterior Chamber Needle, 30 g. Angled. 5 mm angled tip. Overall length 20 mm. 5/box....
Anterior Chamber Needle, 23 g. Angled. 7 mm angled tip. Overall length 23 mm. 5/box....
Anterior Chamber Needle, 20 g. Angled. 7 mm angled tip. Overall length 23 mm. 5/box....
Hydrodissection / Aspiration Cannula, 25 g. Angled with right hook. 10 mm angled shaft with 2.5 mm right hook tip. Overall length 20 mm. 5/box....
Medicine Products: